CARLSBAD, Calif., April 18, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) announced today that it is partnering with Ridom GmbH (Munster, Germany) to make SeqSphere+ whole genome bacterial typing software available for Ion Torrent users. This software enables any lab to perform fast, affordable, and automated high-resolution bacterial typing on the Ion Personal Genome Machine® (PGM™) sequencer.
Up to now, typing methods have lacked discriminatory power, been difficult to standardize, or been labor intensive. SeqSphere+ automated software enables any microbiologist to use a genome-wide approach, typing hundreds to thousands of genes, resulting in higher discrimination and more accurate typing of bacteria.
"It is our aim to deliver a fully integrated turnkey solution for public health and clinical research microbiology," said Dr. Dag Harmsen, University Hospital Muenster, Germany, who is also co-managing director of Ridom and was central in sequencing the deadly E. coli O104:H4 that killed more than 40 people in Germany in 2011. "Together our solution provides an easy workflow with nearly no user intervention, delivering high-quality results using the Ion PGM System. We are excited and feel privileged to work together with the developer/vendor of the fastest evolving benchtop NGS platform, Ion Torrent."
The Ion PGM Sequencer is already in use for subtyping flu viruses by the Global Influenza Network, a collaborative effort between Life Technologies and scientists at a number of the world's leading government public health organizations, veterinary agencies and research institutes. The network focuses on increasing speed, cost effectiveness and accuracy of influenza monitoring and vaccine development. Members share tools, experience and data using the PathAmp™ FluA Reagents and the Ion PGM™ sequencer.
Bacterial typing using Ion Torrent technology is fast and affordable. Bacterial typing can be performed in less than a day from library prep to data analysis. The complete solution includes:
- Ion Xpress® Plus Fragment Library Kit for library construction,
- Ion Chef® System for high throughput sequencing or Ion OneTouch® 2 System to automate template preparation,
- Ion PGM® Sequencer and Ion Chips with the 400 base-pair kit for long, accurate reads in as little as three hours,
- Torrent Suite Software & Ridom SeqSphere+ Software for easy data analysis & assembly.
SeqSphere+ features include:
DNA re-sequencing editor edits and analyzes de novo (.ace) or reference-mapped assemblies (.bam) of NGS data (e.g., MLST, MLST+). Auto-correction of homopolymer related InDel errors.
Analytical tools select data entries from a comparison table for epidemiologic, evolutionary or functional analysis. Cluster and visualize data entries by using minimum spanning or UPGMA/Neighbor Joining trees.
Database to store, search, retrieve, export and create reports from your epidemiologic and DNA sequence data stored in an integrated database. Search new sequence entries against stored data.
Bacteria typing is automatically performed with user defined quality parameters (e.g., coverage, stop codons, frame shift detection, etc.) using public or self-defined query libraries and task templates.
Products referenced above are For Research Use only, not for use in diagnostic procedures.
About Life Technologies Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact :
SOURCE Life Technologies Corporation